Investing.com – It has been a mixed week for stocks, and despite the slight rise on Friday, U.S. indices look set to close the week lower. Even so, there have been some big-name moves.
Here are Investing.com’s stocks of the week:
Banking stocks
Banks kicked off earnings season, with Citigroup, Wells Fargo, Bank of America, Goldman Sachs, JP Morgan, and Morgan Stanley all posting EPS beats.
However, only Morgan Stanley and Goldman Sachs posted gains in the session following their releases, rising 5.8% and 4.6%, respectively.
Meanwhile, JP Morgan fell 4.2%, Bank of America declined 3.4%, Wells Fargo fell 4.6%, and Citigroup dropped 3.6%.
Coreweave
CoreWeave stock rose 12.2% Monday and has rallied over 28% in the last week.
Monday’s performance was linked to CEO Michael Intrator’s comments on the Big Technology Podcast last week, where he and Chief Strategy Officer Brian Venturo rebutted arguments about GPU useful life, a concern that has weighed on AI infrastructure companies.
Meanwhile, JPMorgan analysts said in a note on Friday that meetings with CRWV management “underscored ongoing strength in the demand environment, an expanding and diversifying customer base / pipeline, improved visibility driven by lengthening contract durations, and CoreWeave’s market differentiation and value proposition, which continues to place it among the leaders in the AI hyperscaler market.”
Moderna
Moderna rose 17% in Tuesday’s session and is up 20% in the last week. The shares were given a lift after the company raised its full-year 2025 revenue forecast to approximately $1.9 billion, $100 million above the midpoint of the $1.6 to $2 billion range communicated in its 3Q25 earnings call.
The company also reiterated its target of up to 10% revenue growth in 2026.
Following the announcement, RBC Capital analyst Luca Issi stated that the quarter “was generally in line, and we like a company that is much more financially disciplined and has meaningful catalysts in 2026.”
“However, we also note that top- line returning to growth in 2026 may have some risk,” he added.
Penumbra
Penumbra stock rallied on Thursday, climbing 10.8% in the last week following news that Boston Scientific has agreed to acquire medical technology company in a transaction valued at roughly $14.5 billion.
Under the terms of the agreement, Penumbra shareholders will receive $374 per share, representing a premium of about 19.3% to the stock’s previous closing price. The deal is expected to be completed later in 2026.
Leerink Partners analyst Mike Kratky stated: “We see clear strategic rationale for this deal given our view that PEN’s product portfolio is complementary to BSX’s Cardio portfolio, supporting its entry into the mechanical thrombectomy space."
